Anti-proliferative effects of γ-tocotrienol are associated with suppression of c-Myc expression in mammary tumour cells

Cell Proliferation

Volumn 48, Issue 4, 2015, Pages 421-435

  Parajuli, P ^a   Tiwari, R V ^a   Sylvester, P W ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOTRIENOL; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; GAMMA TOCOTRIENOL; ISOMERASE; KI 67 ANTIGEN; LITHIUM CHLORIDE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN KINASE B; PROTEIN P27; RAS PROTEIN; SERINE THREONINE PHOSPHATASE; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; CHROMAN DERIVATIVE; PLASTOCHROMANOL 8;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST EPITHELIUM CELL; BREAST TUMOR; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MCF 7 CELL LINE; MTT ASSAY; NONHUMAN; ONCOGENE C MYC; POPULATION GROWTH; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAINING; TREATMENT RESPONSE; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; BREAST; BREAST NEOPLASMS; DOWN REGULATION; DRUG EFFECTS; GENETICS; METABOLISM; MOUSE; PATHOLOGY; TUMOR CELL LINE;

ALPHA-TOCOPHEROL; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMANS; DOWN-REGULATION; FEMALE; HUMANS; MCF-7 CELLS; MICE; MICE, INBRED BALB C; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; VITAMIN E;

EID: 84936891330     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/cpr.12196     Document Type: Article

References (39)

1. Amati B, Brooks MW, Levy N, Littlewood TD, Evan GI, Land H (1993) Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell 72, 233-245.
2. Meyer N, Penn LZ (2008) Reflecting on 25 years with MYC. Nat. Rev. Cancer 8, 976-990.
3. D'Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE et al. (2001) c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat. Med. 7, 235-239.
4. Hynes NE, Stoelzle T (2009) Key signalling nodes in mammary gland development and cancer: Myc. Breast Cancer Res. 11, 210.
5. Wang YH, Liu S, Zhang G, Zhou CQ, Zhu HX, Zhou XB et al. (2005) Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res. 7, R220-R228.
6. Junttila MR, Westermarck J (2008) Mechanisms of MYC stabilization in human malignancies. Cell Cycle 7, 592-596.
7. Sears RC (2004) The life cycle of C-myc: from synthesis to degradation. Cell Cycle 3, 1133-1137.
8. Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296, 1655-1657.
9. Zhang X, Farrell AS, Daniel CJ, Arnold H, Scanlan C, Laraway BJ et al. (2012) Mechanistic insight into Myc stabilization in breast cancer involving aberrant Axin1 expression. Proc. Natl Acad. Sci. USA 109, 2790-2795.
10. McIntyre BS, Briski KP, Gapor A, Sylvester PW (2000) Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. Proc. Soc. Exp. Biol. Med. 224, 292-301.
11. Tiwari RV, Parajuli P, Sylvester PW (2014) gamma-Tocotrienol-induced autophagy in malignant mammary cancer cells. Exp. Biol. Med. (Maywood) 239, 33-44.
12. Ayoub NM, Akl MR, Sylvester PW (2013) Combined gamma-tocotrienol and Met inhibitor treatment suppresses mammary cancer cell proliferation, epithelial-to-mesenchymal transition and migration. Cell Prolif. 46, 538-553.
13. Bachawal SV, Wali VB, Sylvester PW (2010) Combined gamma-tocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells. Anticancer Res. 30, 429-437.
14. Sylvester PW, Ayoub NM (2013) Tocotrienols target PI3K/Akt signaling in anti-breast cancer therapy. Anticancer Agents Med. Chem. 13, 1039-1047.
15. Sun W, Wang Q, Chen B, Liu J, Liu H, Xu W (2008) Gamma-tocotrienol-induced apoptosis in human gastric cancer SGC-7901 cells is associated with a suppression in mitogen-activated protein kinase signalling. Br. J. Nutr. 99, 1247-1254.
16. Xu W, Du M, Zhao Y, Wang Q, Sun W, Chen B (2012) gamma-Tocotrienol inhibits cell viability through suppression of beta-catenin/Tcf signaling in human colon carcinoma HT-29 cells. J. Nutr. Biochem. 23, 800-807.
17. Anderson LW, Danielson KG, Hosick HL (1981) Metastatic potential of hyperplastic alveolar nodule derived mouse mammary tumor cells following intravenous inoculation. Eur. J. Cancer Clin. Oncol. 17, 1001-1008.
18. Danielson KG, Anderson LW, Hosick HL (1980) Selection and characterization in culture of mammary tumor cells with distinctive growth properties in vivo. Cancer Res. 40, 1812-1819.
19. Malaviya A, Sylvester PW (2014) Synergistic Antiproliferative Effects of Combined gamma -Tocotrienol and PPAR gamma Antagonist Treatment Are Mediated through PPAR gamma -Independent Mechanisms in Breast Cancer Cells. PPAR Res. 2014, 439146.
20. Akl MR, Ayoub NM, Abuasal BS, Kaddoumi A, Sylvester PW (2013) Sesamin synergistically potentiates the anticancer effects of gamma-tocotrienol in mammary cancer cell lines. Fitoterapia 84, 347-359.
21. Samant GV, Wali VB, Sylvester PW (2010) Anti-proliferative effects of gamma-tocotrienol on mammary tumour cells are associated with suppression of cell cycle progression. Cell Prolif. 43, 77-83.
22. Wali VB, Bachawal SV, Sylvester PW (2009) Suppression in mevalonate synthesis mediates antitumor effects of combined statin and gamma-tocotrienol treatment. Lipids 44, 925-934.
23. Towbin H, Staehelin T, Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl Acad. Sci. USA 76, 4350-4354.
24. Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki-67 in early breast cancer. J. Clin. Oncol. 23, 7212-7220.
25. Yap SP, Yuen KH, Wong JW (2001) Pharmacokinetics and bioavailability of alpha-, gamma- and delta-tocotrienols under different food status. J. Pharm. Pharmacol. 53, 67-71.
26. Kang J, Sergio CM, Sutherland RL, Musgrove EA (2014) Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells. BMC Cancer 14, 32.
27. Gregory MA, Qi Y, Hann SR (2003) Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J. Biol. Chem. 278, 51606-51612.
28. Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN et al. (2004) The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc. Natl Acad. Sci. USA 101, 9085-9090.
29. Welcker M, Clurman BE (2008) FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer 8, 83-93.
30. Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G et al. (2004) A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat. Cell Biol. 6, 308-318.
31. Xu J, Chen Y, Olopade OI (2010) MYC and Breast Cancer. Genes Cancer 1, 629-640.
32. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR (2000) Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 14, 2501-2514.
33. Shin-Kang S, Ramsauer VP, Lightner J, Chakraborty K, Stone W, Campbell S et al. (2011) Tocotrienols inhibit AKT and ERK activation and suppress pancreatic cancer cell proliferation by suppressing the ErbB2 pathway. Free Radic. Biol. Med. 51, 1164-1174.
34. Massague J (2004) G1 cell-cycle control and cancer. Nature 432, 298-306.
35. Matsumura I, Tanaka H, Kanakura Y (2003) E2F1 and c-Myc in cell growth and death. Cell Cycle 2, 333-338.
36. Pelengaris S, Khan M, Evan G (2002) c-MYC: more than just a matter of life and death. Nat. Rev. Cancer 2, 764-776.
37. Nair SK, Burley SK (2003) X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell 112, 193-205.
38. Darnell JE Jr (2002) Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2, 740-749.
39. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al. (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904-917.